Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 6;12:4741. doi: 10.1038/s41467-021-25066-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Analysis of psoriasis lesional skin of patients at baseline (w0) and after 12 weeks (w12) of adalimumab treatment a Number of CD11c+ DCs, expression of CD83 in CD11c+ dermal dendritic cells (DC) and number of IL-23+ CD11c+ DC per area of analysis (750 × 750 μm) at different time points. Each line represents one patient (n CD11c and CD83 = 17, n IL23 = 11) (p CD11c = 0.0093, CD83 = 0.0012, IL23 = 0.0049). b Representative immunofluorescence images of psoriasis skin showing total number of CD11c+ DCs (top), CD83 expression in CD11c+ DC (middle) and IL23+ CD11c+ DC (bottom) in PASI75 adalimumab responders (R, n = 8–10) and non-responders (NR, n = 6–10). c Violin plot graphs of CD11c+ DC counts (top), CD83 expression in dermal DC (middle) and number of IL23 + DC in adalimumab responders (blue, n = 8–10) and non-responders (red, n = 6–10) at w0 and w12) (p CD11c = 0.043, CD83 = 0.035, IL23 = 0.039). d Number of IL-17A+CD4+ Th17 and IL-17A+CD8+ Tc17 cells per area of analysis at different time points. Each line represents one patient (n Th17 = 13, n Tc17 = 17) (p Th17 = 0.0013, Tc17 = 0.011). e Representative immunofluorescence images of psoriasis skin showing Th17 (top) and Tc17 (bottom) in adalimumab responders (n = 8–10) and NR (n = 6–9). f Violin plot graphs of the number of Th17 and Tc17 cells in lesional skin sections of in adalimumab responders (blue, n Th17 week 0 = 9, n Th17 week 12 = 8, n Tc17 week 0 = 10, n Tc17 week 12 = 9) and non-responders (red, n Th17 week 0 = 9, n Th17 week 12 = 6, n Tc17 week 0 = 9, n Tc17 week 12 = 8) at w0 and w12 (p Th17 = 0.04, Tc17 w0 = 0.028, Tc17 w12 = 0.0037). Wilcoxon test (a bottom panel), or paired t test (a except bottom panel, d), Mann–Whitney U test (c top panel, f) or unpaired t test (c except top panel). All tests are two-sided. Scale bars in (b, e): 100 µm (overview) and 25 µm (insets). Source data are provided as a Source Data file.